Vancouver, British Columbia – April 24, 2026 – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (“SureNano” or the “Company”), parent company of GlucaPharm Inc. (“GlucaPharm”), a biopharmaceutical company developing novel therapeutic multi-receptor GLP-1 agonist peptide for the treatment of Type II Diabetes and Obesity candidates, today announced the planning of a comprehensive U.S. Food and Drug Administration (FDA) pathway Investigational New […]

Vancouver, British Columbia – February 23, 2026 – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (“SureNano” or the “Company”) is pleased to announce that it has completed the acquisition of GlucaPharm Inc. (“GlucaPharm”), a next-generation glucagon-like peptide (“GLP”) pharmaceutical company developing a patented therapeutic candidate designed to address obesity and metabolic disease with improved tolerability and delivery potential. The acquisition […]

SureNano Announces Stock Option Grant   VANCOUVER, BC –  December 12, 2025 – SureNano Science Ltd. (CSE:SURE) (OTCQB:SURNF) (the “Company” or “SureNano”) announces that it has granted 1,500,000 stock options to various directors, officers, and Consultants of the Company. The options will vest immediately and may be exercised at an exercise price of CAD $0.18 per common […]

SureNano Announces Closing of $1,250,000 Private Placement   VANCOUVER, BC –  December 10, 2025 – SureNano Science Ltd. (CSE:SURE) (OTCQB:SURNF) (the “Company” or “SureNano”) is pleased to announce, as a follow-up to its news release dated November 5, 2025, that it has closed its non-brokered private placement to raise $1,250,000 through the issuance of 10,000,000 units (each […]

SureNano Announces Non-binding Letter of Intent to Negotiate Proposed Transaction of GlucaPharm Inc. for GLP-1 Drug Development   VANCOUVER, BC –  November 19, 2025 – SureNano Science Ltd. (CSE:SURE) (OTCQB:SURNF) (the “Company” or “SureNano”) is pleased to announce it has entered into a non-binding letter of intent (the “LOI”) with GlucaPharm Inc (“GlucaPharm”), to conduct legal, technical […]

SureNano Announces Private Placement   November 5, 2025 (Vancouver, BC): SURENANO SCIENCE LTD. (CSE: SURE; OTCQB: SURNF) (the “Company” or “SureNano”) announces its intention to complete a private placement for proceeds of up to $1,250,000 (the “Private Placement”).   The Private Placement will consist of the sale of up to 10,000,000 units (each a “Unit”) […]

SureNano Closes Financing   September 19, 2025 (Vancouver, BC): SURENANO SCIENCE LTD. (CSE: SURE; OTCQB: SURNF) (the “Company” or “SureNano”) announces that at has closed a private placement financing of 2,450,000 common shares at a price of $0.10 per share. Total proceeds of $245,000 were received by the Company, including $85,000 in debt conversion.   […]

SureNano Announces Funding, Debt Settlement and AGSM Results August 22, 2025 (Vancouver, BC): SURENANO SCIENCE LTD. (CSE: SURE; OTCQB: SURNF) (the “Company” or “SureNano”) announces its intention to complete a recapitalization consisting of a debt settlement with an insider for $85,000 (“Debt Settlement”) and a private placement for proceeds of up to $215,000 (the “Private […]

SureNano Annual General and Special Meeting Results   February 12, 2024 (Vancouver, BC): SURENANO SCIENCE LTD. (CSE: SURE; OTCQB: SURNF) (the “Company” or “SureNano”) announces that it held its annual general and special meeting (the “AGM”) held on February 9, 2024.  A total of 12 shareholders voted, in person or by proxy, representing a total […]

SureNano Science Announces DTC Eligibility   Vancouver, B.C. January 17, 2023 – SURENANO SCIENCE LTD. (CSE:SURE)(OTCQB:SURNF) (the “Company” or “SureNano”) has received approval from the Depository Trust Company, making its common shares eligible for electronic clearing and settlement through DTC’s automated processes. SureNano’s common shares are quoted on the OTCQB under the symbol “SURNF.”   […]